Is the IVF success rate in Kyrgyzstan higher than in China? Objective data and difference analysis

Author: Reproductive Medicine Knowledge Editor + 10-year Consultant
Opening Random Mechanism: 5 Patient Misconceptions

—— Patient Misconceptions · Objective Analysis ——

Some people believe that the success rate of IVF in Kyrgyzstan is higher than in China, due to "more advanced overseas technology" or "more lenient policies." Is this view accurate? What factors determine the success rate? Based on public data and industry observations, this article provides a multi-dimensional comparison of IVF success rates between the two countries to help make a more rational judgment.

Is the IVF success rate in Kyrgyzstan higher than in China? Direct answer

Not entirely accurate. Based on existing data and clinical observations, the live birth rate of IVF in top domestic reproductive centers is generally higher than that in top Kyrgyzstan clinics; however, the gap between different hospitals in China is large, while the success rate of certain well-known clinics in Kyrgyzstan is comparable to the upper-middle level in China. Specific comparison is as follows:

Data note: The above are industry experience ranges, depending on individual patient conditions, medication protocols, and embryo quality. Live birth rate refers to the probability of a live birth after a single fresh or frozen embryo transfer.

Why do some people think the success rate in Kyrgyzstan is higher?

This perception mainly stems from three information biases:

• Amplification of individual success stories: The experiences of a few patients who failed multiple times domestically but succeeded in Kyrgyzstan spread within communities, easily creating the impression that "overseas technology is better." However, this overlooks the possibility that these patients may have used PGT, egg donation, or more lenient embryo selection policies in Kyrgyzstan, which might be restricted in China.
• "Selective reporting" due to policy differences: Kyrgyzstan allows chromosomal screening (PGT-A) of embryos with broader indications, and even non-medical gender selection, which is prohibited in China. Some patients equate "being able to do PGT" with "higher success rate," but PGT itself does not increase the live birth rate per single transfer; it reduces the number of failed transfers by screening embryos.
• Psychological suggestion from cost and service: Lower medical costs and more personalized service processes can easily create the illusion that "high cost-effectiveness equals good technology," but success rates are not directly linked to cost.

How do reproductive doctors view the success rate difference between China and Kyrgyzstan?

The core viewpoint from the doctor's perspective is: Success rate is a function of 'patient + embryo + laboratory,' not a function of 'country.' Laboratory quality standards, culture techniques, and embryologist experience do affect outcomes, but the gap between top domestic centers and top Kyrgyzstan clinics in these factors is not large.

Differences between China and Kyrgyzstan in IVF: More than just success rates

Beyond the success rate figures themselves, there are significant differences between the two countries in multiple dimensions of assisted reproduction, which may be more noteworthy than the "success rate" itself:

The most easily overlooked detail: Different statistical methods for success rates

When comparing success rates between the two countries, one key detail is easily overlooked — statistical methods. Domestic reproductive centers usually report "clinical pregnancy rate" (gestational sac seen on ultrasound), while some clinics in Kyrgyzstan report "biochemical pregnancy rate" (positive HCG) or "embryo implantation rate." The latter two figures are higher but have a larger gap from the final live birth. Additionally:

• Whether cancelled cycles are included: Some clinics only count the success rate of "transfer cycles," excluding cycles where egg retrieval or transfer was cancelled, which inflates the data.
• Patient selection criteria: Some Kyrgyzstan clinics have implicit thresholds for patient age and AMH, making it easier to include younger patients with good ovarian function in statistics, leading to an overall higher success rate.
• Impact of multiple pregnancy rate: Some clinics in Kyrgyzstan tend to transfer 2–3 embryos to increase the "success rate," resulting in a higher multiple pregnancy rate, but the maternal and infant risks associated with multiple pregnancies also increase accordingly.

Therefore, when reviewing any success rate data, you should ask for the "live birth rate per egg retrieval cycle," which is an internationally recognized objective indicator.

The most common pitfall: Being misled by "success rate" numbers

In practical consultations, the following three situations most easily lead to wrong decisions:

1. Looking only at the single transfer success rate, ignoring the cumulative live birth rate. The single transfer success rate is greatly affected by the number of embryos. Young patients may obtain multiple blastocysts from one egg retrieval, and the cumulative live birth rate after multiple transfers is much higher than the single transfer data. Do not give up because of a low single transfer number.
2. Being attracted by "guaranteed success" packages. Some clinics in Kyrgyzstan offer "guaranteed success" packages, but they often come with strict patient selection conditions (e.g., AMH ≥ 1.5, age ≤ 38), and the package fee already includes the cost of multiple transfers. It is necessary to carefully calculate the total cost and whether the actual conditions are met.
3. Ignoring follow-up support services. After embryo transfer in Kyrgyzstan, patients need to return to China for luteal support and pregnancy follow-up. Some clinics lack coordination with domestic hospitals, which may lead to poor continuity of care.

Actual process of doing IVF in Kyrgyzstan

If you are indeed considering going to Kyrgyzstan, the complete process generally includes the following steps:

• Remote consultation and evaluation: Submit reports from the last 3 months including hormone panel (FSH, LH, E2), AMH, antral follicle count (AFC), semen analysis, etc., for evaluation by a Kyrgyzstan doctor to determine suitability.
• Visa and travel arrangements: Kyrgyzstan offers e-visas or visa-free entry for Chinese citizens in some cases; it is recommended to confirm the latest policy in advance. The first visit usually requires a stay of 10–14 days (for egg retrieval and embryo transfer).
• Ovarian stimulation and egg retrieval: Complete ovarian stimulation at the local clinic (about 10–12 days). Egg retrieval is usually performed under anesthesia, and you can leave 2 hours after the procedure.
• Embryo culture and PGT: Blastocyst culture is performed on days 5–6 after egg retrieval. If PGT-A is required, samples are taken and sent for testing, with results taking about 7–10 days. During this time, the patient can return home and wait for the embryo results.
• Frozen embryo transfer: Depending on endometrial preparation, return for transfer in a subsequent cycle. This usually requires another stay of 3–5 days.
• Follow-up after returning home: 12–14 days after transfer, have a blood test for HCG locally or in China. If pregnancy is confirmed, continue luteal support and register for obstetric care according to domestic procedures.

Frequently asked questions

Q1: I have low AMH. Is Kyrgyzstan suitable for me?

Low AMH indicates diminished ovarian reserve, resulting in fewer mature eggs retrieved. Regardless of the country, the expected number of eggs retrieved per cycle for patients with AMH < 0.5 ng/ml is usually no more than 3–5, and the cumulative live birth rate is low. Kyrgyzstan's advantage lies in the relatively free choice of PGT or egg donation, but if using your own eggs, the success rate will not significantly improve due to the change in location.

Q2: I have failed IVF twice in China. Is there hope in Kyrgyzstan?

First, analyze the reasons for failure: Is it due to embryo chromosomal abnormalities, endometrial receptivity issues, or laboratory culture environment problems? If it is embryo chromosomal abnormalities (especially in older patients), using PGT in Kyrgyzstan to screen for chromosomally normal embryos for transfer may improve the efficiency of a single transfer. However, if it is an endometrial or immune factor, targeted examination and treatment should be done first in China.

Q3: What is the laboratory standard in Kyrgyzstan?

Several reproductive centers in Bishkek have introduced European-standard embryology laboratories equipped with time-lapse incubators, air purification systems, etc., but the overall number is small. It is recommended to choose clinics with international certifications (such as ISO or JCI) and ask to see the laboratory's quality control data (e.g., blastocyst formation rate, freeze-thaw survival rate).

Q4: What examination reports do I need to prepare?

Typically required: Female — AMH, FSH, LH, E2, antral follicle count (AFC), thyroid function, infectious disease screening (HIV, Hepatitis B, Hepatitis C, Syphilis), chromosome karyotype. Male — Semen analysis, sperm morphology, infectious disease screening, chromosome karyotype. All reports must be translated into English or Russian and be valid within 3–6 months.